BioServe, Beltsville, Md, has introduced ControlMatch, a new line of fully annotated control DNA and serum samples that help biomedical researchers validate new biomarkers and early stage clinical trial drug candidates.

The products allow researchers to select and match control samples to the specific needs of their own DNA and/or serum-based studies by leveraging the company’s global repository of 600,000 human biological samples. Its DNA and serum controls will initially cover type II diabetes, hypertension, and hyperlipidemia, and extend to other disease states in early 2008.
 
The products’ normal samples for type II diabetes, hypertension, and hyperlipidemia are annotated with body mass index (BMI), confirmed normal blood glucose levels, confirmed normal blood pressure and cholesterol levels, and a family history of health status, and ethnicity determined by data collected on three generations. Researchers can identify one-to-one matched controls for extended criteria such as age, gender, ethnicity, BMI, diet, and a host of lifestyle factors. It includes clinically confirmed negative results enabling researchers to further confirm that their markers are valued against the correct set of controls.

The company specializes in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Pharma, biotech, and diagnostic firms collaborate with the company to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests to promote wellness worldwide.